logo

Revance Therapeutics, Inc. (RVNC)



Trade RVNC now with
  Date
  Headline
1/9/2018 6:06:39 AM Hercules Capital Achieves More Than $880 Mln In New Commitments In 2017
1/8/2018 8:37:08 AM Revance Announces Interim Phase 2a Results For RT002 In Treating Plantar Fasciitis
12/28/2017 4:26:12 AM Watch These 6 Biotech Stocks
12/11/2017 4:10:28 PM Revance Announces Closing Of Public Offering Of Common Stock
12/7/2017 8:35:49 AM Revance Therapeutics Prices Public Offering Of 5.34 Mln Shares At $31.00/shr
12/5/2017 4:50:48 PM Revance Announces Proposed Public Offering Of Common Stock
12/5/2017 7:43:54 AM Revance Therapeutics, Trading Halted; Expected To Resume At 8:00 AM ET
12/5/2017 7:32:39 AM Revance’s RT002 Meets Primary And All Secondary Endpoints, Achieves 6-Month Duration In Pivotal SAKURA Phase 3 Trials
10/18/2017 8:05:13 AM Revance Completes Patient Enrollment In Phase 2 Program For RT002 Injectable In Management Of Plantar Fasciitis
9/6/2017 7:34:50 AM Revance Therapeutics Appoints Mark Foley To Board
3/7/2017 8:11:36 AM Revance Therapeutics Completes Patient Enrollment In Two Pivotal Trials Of SAKURA Phase 3 Program
2/28/2017 7:30:17 AM William Blair Reiterates Revance Therapeutics, Inc. (RVNC) At Outperform